Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emicizumab Prophylaxis in Hemophilia A Patients (HAVEN 5)
NCT03315455Phase 3Completed
- Sponsor
- Roche
- Start
- Apr 2018
- Primary completion
- Aug 2022
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 3 trial of emicizumab in hemophilia A, sponsored by Roche. Started Apr 2018; status: completed.
02
Drugs
emicizumab
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT03315455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03315455.